Weighty Matters: Viking To Showcase Potential Of Dual GLP-1/GIP Agonist VK2735 At ObesityWeek 2025

ObesityWeek 2025, an annual international conference for obesity researchers and clinicians, is scheduled to take place from November 4 to 7 in Atlanta, Georgia. According to the latest data from the Centers for Disease Control and Prevention (CDC), obesity remains highly prevalent among U.S. adults - more than 100 million are living with obesity, and over 22 million have severe obesity. Obesity is defined as having a body mass index (BMI) of 30.0 or higher, while severe obesity is defined as a BMI of 40.0 or higher.

At the ObesityWeek 2025, Viking Therapeutics Inc. (VKTX) will be highlighting clinical data from its VK2735 obesity program on November 5, 2025.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com